Strong decline of intrahepatic HDV markers and signs of liver inflammation after 48 weeks of treatment with Bulevirtide in chronic hepatitis D patients: Combined intrahepatic results from the clinical trials MYR203 and MYR301

Lena Allweiss,Annika Volmari,Yvonne Ladiges, Corinna Eggers,Vithika Suri,Jeffrey J. Wallin,John F. Flaherty,Dmitry Manuilov,Marc Lütgehetmann,Heiner Wedemeyer,Stephan Urban,Jan-Hendrik Bockmann,Maura Dandri

Zeitschrift Fur Gastroenterologie（2023）

引用 1|浏览10

暂无评分

摘要

Background Bulevirtide (BLV, Hepcludex) is the only approved treatment for patients chronically infected with HDV in Europe. BLV is a first-in-class entry inhibitor blocking the HBV/HDV-receptor sodium taurocholate co-transporting polypeptide (NTCP).

查看译文

关键词

intrahepatic hdv markers,liver inflammation,combined intrahepatic results,bulevirtide,clinical trials myr203

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要